Rimonabant Clinical Trials Show Weight Loss, Better Lipids, and Smoking Cessation Benefits
Four large trials of the CB1 blocker rimonabant showed significant weight loss, reduced waist circumference, improved lipid levels, better blood sugar control, and increased smoking quit rates compared to placebo.
Quick Facts
What This Study Found
This review from the Journal of the American College of Cardiology summarized clinical trial evidence for rimonabant, the first selective CB1 cannabinoid receptor blocker developed for cardiometabolic risk management.
Across four large trials, rimonabant 20 mg daily produced greater weight loss and waist circumference reduction compared to placebo after one year. The drug also improved serum lipid profiles and glycemic control in both prediabetes patients and type 2 diabetics.
At the same dose, rimonabant significantly increased cigarette smoking quit rates compared to placebo. The primary side effect was mild nausea. The review positioned rimonabant as a potential adjunct to lifestyle modification for managing multiple cardiometabolic risk factors simultaneously.
Key Numbers
Four large RCTs reviewed. Rimonabant 20 mg daily vs. placebo. Outcomes: greater weight loss, reduced waist circumference, improved serum lipids, improved glycemic control, increased smoking quit rates. Primary side effect: mild nausea.
How They Did This
Clinical review summarizing results from four large randomized controlled trials (the RIO program) of rimonabant for cardiometabolic outcomes. Evaluated weight, waist circumference, lipids, glycemic control, and smoking cessation.
Why This Research Matters
The concept of treating multiple cardiometabolic risk factors with a single drug by targeting the endocannabinoid system was groundbreaking. The fact that a cannabinoid receptor blocker could simultaneously improve weight, metabolic markers, and smoking rates illustrated how deeply the endocannabinoid system is involved in these interconnected health behaviors.
The Bigger Picture
Rimonabant was approved in Europe in 2006 but withdrawn in 2008 after post-marketing reports of depression and suicidal ideation, which were not fully apparent in the initial trials. This outcome illustrates the risks of broadly blocking a receptor system involved in mood regulation alongside metabolism.
What This Study Doesn't Tell Us
This review was published before the full safety signal emerged. The optimistic framing of "mild nausea" as the primary side effect did not capture the psychiatric risks that became apparent with wider use. The one-year trial duration may have been insufficient to detect longer-term risks.
Questions This Raises
- ?Can the metabolic benefits of CB1 blockade be achieved without the psychiatric side effects?
- ?Would peripherally-restricted CB1 antagonists (that do not enter the brain) provide metabolic benefits safely?
Trust & Context
- Key Stat:
- Rimonabant improved weight, waist circumference, lipids, blood sugar, and smoking cessation in four large trials
- Evidence Grade:
- Review of four large RCTs with robust cardiometabolic outcomes. Strong evidence for efficacy but published before full safety profile was known.
- Study Age:
- Published in 2006 in JACC. Rimonabant was withdrawn in 2008 due to depression and suicidal ideation. Research into safer CB1 modulators continues.
- Original Title:
- Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
- Published In:
- Journal of the American College of Cardiology, 47(10), 1919-26 (2006)
- Authors:
- Gelfand, Eli V, Cannon, Christopher P
- Database ID:
- RTHC-00227
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Did the cannabinoid receptor blocker work for weight loss?
Yes. Across four large trials, rimonabant 20 mg produced significant weight loss and waist circumference reduction compared to placebo. However, the drug was later withdrawn due to psychiatric side effects (depression, suicidal ideation) that were not fully apparent in the initial trials.
Can blocking cannabinoid receptors help quit smoking?
Rimonabant significantly increased smoking quit rates compared to placebo. This makes sense given the endocannabinoid system's role in reward processing. However, the drug's psychiatric side effects prevented it from remaining available for this use.
Read More on RethinkTHC
- cannabis-cardiovascular-heart-risk-stroke
- cannabis-heart-cardiovascular-risk
- coughing-up-stuff-after-quitting-weed
- lung-recovery-after-quitting-smoking-weed
- lung-recovery-quitting-weed
- quitting-weed-female-hormones
- quitting-weed-weight-gain-loss-diet-appetite
- sex-after-quitting-weed
- weed-DUI-driving-impaired-cannabis-laws
- weed-acne-skin
- weed-fertility-sperm
- weed-gut-digestion-problems
- weed-heart-health
- weed-testosterone-levels
- cannabis-and-your-body-what-research-shows
- why-does-weed-make-you-hungry-munchies
- why-does-weed-make-eyes-red-blood-vessel
- why-does-weed-make-food-taste-better
- why-does-weed-make-heart-race-cardiovascular
- thc-and-blood-pressure-medication-interactions
Cite This Study
https://rethinkthc.com/research/RTHC-00227APA
Gelfand, Eli V; Cannon, Christopher P. (2006). Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.. Journal of the American College of Cardiology, 47(10), 1919-26.
MLA
Gelfand, Eli V, et al. "Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.." Journal of the American College of Cardiology, 2006.
RethinkTHC
RethinkTHC Research Database. "Rimonabant: a cannabinoid receptor type 1 blocker for manage..." RTHC-00227. Retrieved from https://rethinkthc.com/research/gelfand-2006-rimonabant-a-cannabinoid-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.